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Cell signaling proteomics in colorectal cancer
Madoz-Gúrpide J, Fernández-Carbonie F, Alfonso P, Casal I.
To gain further insight into alterations in cellular 
pathways, tumor profi ling and marker discovery in 
colorectal cancer (CRC) we have used a new antibo-
dy microarray specifi c for cell signaling. Soluble pro-
tein extracts were prepared from paired tumor/normal 
biopsies of 11 patients diagnosed of colorectal carci-
noma at different stages, four liver carcinomas were 
used as a reference. Antibody microarray analysis 
identifi ed 46 proteins that were differentially expre-
ssed between normal colorectal epithelium and ade-
nocarcinoma. These proteins gave a specifi c signature 
for CRC, different from other tumors, as well as a 
panel of novel markers and potential targets for CRC. 
Twenty-four proteins were validated by using a spe-
cifi c colorectal cancer tissue microarray and immu-
noblotting analysis. Together with some previously 
well known deregulated proteins in CRC (β-catenin, 
c-myc, or p63), we have found new potential markers 
preferentially expressed in CRC tumors: cytokeratin 
13, calcineurin, Chk1, clathrin light chain, MAPK3, 
phospho-PTK2/FAK (S910) and MDM2. Chk1 anti-
bodies were particularly effective in discriminating 
between tumoral and normal mucosa in CRC. Mo-
reover, a global picture of alterations in signaling pa-
thways in CRC was observed, including a signifi cant 
up-regulation of different components of the EGFR 
and Wnt/β-catenin pathways and the down-regulation 
of p14ARF. The experimental approach described here 
should be applicable to other pathologies and neopla-
sic processes.
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